Stefan Knapp

List of Publications by Year in Descending Order

302 papers	20,101 citations	72 h-index	136 g-index
340 ext. papers	24,211 ext. citations	9.7 avg, IF	6.8 L-index

#	Paper	IF	Citations
302	TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy.. *Journal of Medicinal Chemistry*, **2022**,	8.3	2
301	DNA topoisomerase inhibition with the HIF inhibitor acriflavine promotes transcription of lncRNAs in endothelial cells.. *Molecular Therapy - Nucleic Acids*, **2022**, 27, 1023-1035	10.7	1
300	Resistance to kinase inhibition through shortened target engagement.. *Molecular and Cellular Oncology*, **2022**, 9, 2029999	1.2	
299	Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119,	11.5	2
298	Synthesis and biological evaluation of Haspin inhibitors: Kinase inhibitory potency and cellular activity.. *European Journal of Medicinal Chemistry*, **2022**, 236, 114369	6.8	0
297	Development of novel urea-based ATM kinase inhibitors with subnanomolar cellular potency and high kinome selectivity.. *European Journal of Medicinal Chemistry*, **2022**, 235, 114234	6.8	0
296	Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress.. *Nature Cancer*, **2022**, 3, 156-172	15.4	2
295	Enabling pseudokinases as potential drug targets.. *Methods in Enzymology*, **2022**, 667, 663-683	1.7	
294	BET bromodomain inhibitors.. *Current Opinion in Chemical Biology*, **2022**, 68, 102148	9.7	4
293	LRRK2 dynamics analysis identifies allosteric control of the crosstalk between its catalytic domains.. *PLoS Biology*, **2022**, 20, e3001427	9.7	4
292	Calcium/calmodulin-dependent protein kinase kinase 2 regulates hepatic fuel metabolism.. *Molecular Metabolism*, **2022**, 101513	8.8	0
291	Novel, highly potent PROTACs targeting AURORA-A kinase. *Current Research in Chemical Biology*, **2022**, 100032		0
290	Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	6
289	Nanopore Enzymology to Study Protein Kinases and Their Inhibition by Small Molecules. *Methods in Molecular Biology*, **2021**, 2186, 95-114	1.4	
288	The Transcriptional Repressor Orphan Nuclear Receptor TLX Is Responsive to Xanthines.. *ACS Pharmacology and Translational Science*, **2021**, 4, 1794-1807	5.9	2
287	Closantel is an allosteric inhibitor of human Taspase1.. *IScience*, **2021**, 24, 103524	6.1	0
286	Structure-Based Design of Dual Partial Peroxisome Proliferator-Activated Receptor Agonists/Soluble Epoxide Hydrolase Inhibitors. *Journal of Medicinal Chemistry*, **2021**, 64, 17259-17276	8.3	1

285	Inhibitors of the Hippo Pathway Kinases STK3/MST2 and STK4/MST1 Have Utility for the Treatment of Acute Myeloid Leukemia. *Journal of Medicinal Chemistry*, **2021**,	8.3	1
284	Selective BH3 mimetics synergize with BET inhibition to induce mitochondrial apoptosis in rhabdomyosarcoma cells.. *Neoplasia*, **2021**, 24, 109-119	6.4	1
283	Structure and Inhibitor Binding Characterization of Oncogenic MLLT1 Mutants. *ACS Chemical Biology*, **2021**, 16, 571-578	4.9	2
282	Structural Insights into Plasticity and Discovery of Remdesivir Metabolite GS-441524 Binding in SARS-CoV-2 Macrodomain. *ACS Medicinal Chemistry Letters*, **2021**, 12, 603-609	4.3	17
281	7-(2-Anilinopyrimidin-4-yl)-1-benzazepin-2-ones Designed by a "Cut and Glue" Strategy Are Dual Aurora A/VEGF-R Kinase Inhibitors. *Molecules*, **2021**, 26,	4.8	1
280	Demonstrating Ligandability of the LC3A and LC3B Adapter Interface. *Journal of Medicinal Chemistry*, **2021**, 64, 3720-3746	8.3	4
279	Development of a potent and selective chemical probe for the pleiotropic kinase CK2. *Cell Chemical Biology*, **2021**, 28, 546-558.e10	8.2	14
278	Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics. *Journal of Medicinal Chemistry*, **2021**, 64, 5123-5136	8.3	2
277	Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine core. *European Journal of Medicinal Chemistry*, **2021**, 215, 113299	6.8	6
276	A Chemical Toolbox for Labeling and Degrading Engineered Cas Proteins. *Jacs Au*, **2021**, 1, 777-785		1
275	Structure-kinetic relationship reveals the mechanism of selectivity of FAK inhibitors over PYK2. *Cell Chemical Biology*, **2021**, 28, 686-698.e7	8.2	13
274	Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy. *Oncogene*, **2021**, 40, 3637-3654	9.2	8
273	Endogenous vitamin E metabolites mediate allosteric PPAR activation with unprecedented co-regulatory interactions. *Cell Chemical Biology*, **2021**, 28, 1489-1500.e8	8.2	8
272	Large-Scale Recombinant Production of the SARS-CoV-2 Proteome for High-Throughput and Structural Biology Applications. *Frontiers in Molecular Biosciences*, **2021**, 8, 653148	5.6	12
271	Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders. *Journal of Medicinal Chemistry*, **2021**, 64, 10682-10710	8.3	9
270	C81-evoked inhibition of the TNFR1-NF B pathway during inflammatory processes for stabilization of the impaired vascular endothelial barrier for leukocytes. *FASEB Journal*, **2021**, 35, e21656	0.9	1
269	Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells. *Journal of Medicinal Chemistry*, **2021**, 64, 8727-8738	8.3	3
268	Conformation and dynamics of the kinase domain drive subcellular location and activation of LRRK2. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	11

267	Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors. *Journal of Medicinal Chemistry*, **2021**, 64, 8142-8160	8.3	4
266	Synthetic Opportunities and Challenges for Macrocyclic Kinase Inhibitors. *Journal of Medicinal Chemistry*, **2021**, 64, 7991-8009	8.3	5
265	Conformational plasticity of the ULK3 kinase domain. *Biochemical Journal*, **2021**, 478, 2811-2823	3.8	2
264	The Small-Molecule Inhibitor MRIA9 Reveals Novel Insights into the Cell Cycle Roles of SIK2 in Ovarian Cancer Cells. *Cancers*, **2021**, 13,	6.6	1
263	Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3 Inhibitors. *Journal of Medicinal Chemistry*, **2021**,	8.3	3
262	Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. *Cell Chemical Biology*, **2021**, 28, 134-147.e14	8.2	13
261	Mapping the Endothelial Cell -Sulfhydrome Highlights the Crucial Role of Integrin Sulfhydration in Vascular Function. *Circulation*, **2021**, 143, 935-948	16.7	20
260	Integrated analysis of Shank1 PDZ interactions with C-terminal and internal binding motifs. *Current Research in Structural Biology*, **2021**, 3, 41-50	2.8	3
259	The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	18
258	Combined Cardioprotective and Adipocyte Browning Effects Promoted by the Eutomer of Dual sEH/PPAR Modulator. *Journal of Medicinal Chemistry*, **2021**, 64, 2815-2828	8.3	4
257	Deciphering the LRRK code: LRRK1 and LRRK2 phosphorylate distinct Rab proteins and are regulated by diverse mechanisms. *Biochemical Journal*, **2021**, 478, 553-578	3.8	8
256	Trends in kinase drug discovery: targets, indications and inhibitor design. *Nature Reviews Drug Discovery*, **2021**, 20, 839-861	64.1	62
255	Controlling the Covalent Reactivity of a Kinase Inhibitor with Light. *Angewandte Chemie - International Edition*, **2021**, 60, 20178-20183	16.4	8
254	Controlling the Covalent Reactivity of a Kinase Inhibitor with Light. *Angewandte Chemie*, **2021**, 133, 20340-20345	3.6	2
253	Discovery of a Potent Dual SLK/STK10 Inhibitor Based on a Maleimide Scaffold. *Journal of Medicinal Chemistry*, **2021**, 64, 13259-13278	8.3	0
252	Development of a Selective Dual Discoidin Domain Receptor (DDR)/p38 Kinase Chemical Probe. *Journal of Medicinal Chemistry*, **2021**, 64, 13451-13474	8.3	0
251	Design and Development of a Chemical Probe for Pseudokinase Ca/calmodulin-Dependent Ser/Thr Kinase. *Journal of Medicinal Chemistry*, **2021**, 64, 14358-14376	8.3	0
250	Single tracer-based protocol for broad-spectrum kinase profiling in live cells with NanoBRET. *STAR Protocols*, **2021**, 2, 100822	1.4	1

249	Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. *Cancer Research*, **2021**, 81, 1627-1632	10.1	7
248	How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition-The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine. *Molecules*, **2020**, 25,	4.8	6
247	Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	6
246	Structure of LRRK2 in Parkinson's disease and model for microtubule interaction. *Nature*, **2020**, 588, 344-349	50.4	60
245	Radiolabeled cCPE Peptides for SPECT Imaging of Claudin-4 Overexpression in Pancreatic Cancer. *Journal of Nuclear Medicine*, **2020**, 61, 1756-1763	8.9	4
244	Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma. *Oncogene*, **2020**, 39, 4770-4779	9.2	16
243	Function, Structure and Topology of Protein Kinases. *Topics in Medicinal Chemistry*, **2020**, 1-24	0.4	3
242	Discovery of Highly Selective Inhibitors of Calmodulin-Dependent Kinases That Restore Insulin Sensitivity in the Diet-Induced Obesity Mouse Model. *Journal of Medicinal Chemistry*, **2020**, 63, 6784-6801	8.3	4
241	Bioisosteric Replacement of Arylamide-Linked Spine Residues with -Acylhydrazones and Selenophenes as a Design Strategy to Novel Dibenzosuberone Derivatives as Type I 1/2 p38 MAP Kinase Inhibitors. *Journal of Medicinal Chemistry*, **2020**, 63, 7347-7354	8.3	5
240	Backbone resonance assignments of the catalytic and regulatory domains of Ca/calmodulin-dependent protein kinase 1D. *Biomolecular NMR Assignments*, **2020**, 14, 221-225	0.7	
239	A Highly Selective Chemical Probe for Activin Receptor-like Kinases ALK4 and ALK5. *ACS Chemical Biology*, **2020**, 15, 862-870	4.9	7
238	Co-inhibition of BET proteins and PI3K triggers mitochondrial apoptosis in rhabdomyosarcoma cells. *Oncogene*, **2020**, 39, 3837-3852	9.2	7
237	Quantifying Target Occupancy of Small Molecules Within Living Cells. *Annual Review of Biochemistry*, **2020**, 89, 557-581	29.1	20
236	Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma. *International Journal of Cancer*, **2020**, 147, 2847-2861	7.5	16
235	Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases. *Molecular Cell*, **2020**, 79, 390-405.e7	17.6	30
234	l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPAR *Journal of Medicinal Chemistry*, **2020**, 63, 6727-6740	8.3	12
233	A Selective Modulator of Peroxisome Proliferator-Activated Receptor with an Unprecedented Binding Mode. *Journal of Medicinal Chemistry*, **2020**, 63, 4555-4561	8.3	3
232	Effects of epigenetic pathway inhibitors on corticotroph tumour AtT20 cells. *Endocrine-Related Cancer*, **2020**, 27, 163-174	5.7	3

231	Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib. *Oncotarget*, **2020**, 11, 535-549	3.3	15
230	Decoding the Papain Inhibitor from as Being Hydroxylated Chymostatin Derivatives: Purification, Structure Analysis, and Putative Biosynthetic Pathway. *Journal of Natural Products*, **2020**, 83, 2983-2995	4.9	1
229	The novel dual BET/HDAC inhibitor TW09 mediates cell death by mitochondrial apoptosis in rhabdomyosarcoma cells. *Cancer Letters*, **2020**, 486, 46-57	9.9	10
228	Activation by substoichiometric inhibition. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 1414-1418	11.5	5
227	Nucleotide Binding, Evolutionary Insights, and Interaction Partners of the Pseudokinase Unc-51-like Kinase 4. *Structure*, **2020**, 28, 1184-1196.e6	5.2	9
226	Aminothiazolones as potent, selective and cell active inhibitors of the PIM kinase family. *Bioorganic and Medicinal Chemistry*, **2020**, 28, 115724	3.4	1
225	Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor. *European Journal of Medicinal Chemistry*, **2020**, 208, 112770	6.8	6
224	PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase. *Nature Chemical Biology*, **2020**, 16, 1179-1188	11.7	31
223	Selective targeting of the and DFG-out pocket in p38 MAPK. *European Journal of Medicinal Chemistry*, **2020**, 208, 112721	6.8	7
222	Design of new disubstituted imidazo[1,2-]pyridazine derivatives as selective Haspin inhibitors. Synthesis, binding mode and anticancer biological evaluation. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2020**, 35, 1840-1853	5.6	3
221	Development of a chemical probe against NUDT15. *Nature Chemical Biology*, **2020**, 16, 1120-1128	11.7	5
220	The orphan nuclear receptor Nurr1 is responsive to non-steroidal anti-inflammatory drugs. *Communications Chemistry*, **2020**, 3,	6.3	14
219	A Chemical Probe for Dark Kinase STK17B Derives Its Potency and High Selectivity through a Unique P-Loop Conformation. *Journal of Medicinal Chemistry*, **2020**, 63, 14626-14646	8.3	3
218	Pan-SMARCA/PB1 Bromodomain Inhibitors and Their Role in Regulating Adipogenesis. *Journal of Medicinal Chemistry*, **2020**, 63, 14680-14699	8.3	6
217	Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer. *Journal of Medicinal Chemistry*, **2020**, 63, 14609-14625	8.3	5
216	Catalytic Domain Plasticity of MKK7 Reveals Structural Mechanisms of Allosteric Activation and Diverse Targeting Opportunities. *Cell Chemical Biology*, **2020**, 27, 1285-1295.e4	8.2	8
215	DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity. *Journal of Medicinal Chemistry*, **2020**, 63, 10224-10234	8.3	12
214	p63 uses a switch-like mechanism to set the threshold for induction of apoptosis. *Nature Chemical Biology*, **2020**, 16, 1078-1086	11.7	9

213	Kinase Domain Is a Dynamic Hub for Driving LRRK2 Allostery. *Frontiers in Molecular Neuroscience*, **2020**, 13, 538219	6.1	7
212	Crystal Structure and Inhibitor Identifications Reveal Targeting Opportunity for the Atypical MAPK Kinase ERK3. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
211	Comparative structural analyses and nucleotide-binding characterization of the four KH domains of FUBP1. *Scientific Reports*, **2020**, 10, 13459	4.9	1
210	Next-generation epigenetic inhibitors. *Science*, **2020**, 368, 367-368	33.3	12
209	Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain. *Journal of Medicinal Chemistry*, **2019**, 62, 8443-8460	8.3	7
208	New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis. *European Journal of Medicinal Chemistry*, **2019**, 166, 304-317	6.8	18
207	Synthesis and Structure-Activity Relationships of 3,5-Disubstituted-pyrrolo[2,3- b]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with Antiviral Activity. *Journal of Medicinal Chemistry*, **2019**, 62, 5810-5831	8.3	23
206	A chemical toolbox for the study of bromodomains and epigenetic signaling. *Nature Communications*, **2019**, 10, 1915	17.4	43
205	Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. *Cell Chemical Biology*, **2019**, 26, 818-829.e9	8.2	26
204	Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity. *Journal of Medicinal Chemistry*, **2019**, 62, 2618-2637	8.3	33
203	SGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK). *Journal of Medicinal Chemistry*, **2019**, 62, 2830-2836	8.3	30
202	A Novel Biphenyl-based Chemotype of Retinoid X Receptor Ligands Enables Subtype and Heterodimer Preferences. *ACS Medicinal Chemistry Letters*, **2019**, 10, 1346-1352	4.3	6
201	High-Throughput Purification of Protein Kinases from Escherichia coli and Insect Cells. *Methods in Molecular Biology*, **2019**, 2025, 191-202	1.4	3
200	Fast Iterative Synthetic Approach toward Identification of Novel Highly Selective p38 MAP Kinase Inhibitors. *Journal of Medicinal Chemistry*, **2019**, 62, 10757-10782	8.3	10
199	Lessons from LIMK1 enzymology and their impact on inhibitor design. *Biochemical Journal*, **2019**, 476, 3197-3209	3.8	3
198	Conservation of structure, function and inhibitor binding in UNC-51-like kinase 1 and 2 (ULK1/2). *Biochemical Journal*, **2019**, 476, 875-887	3.8	19
197	[]-Annulated Halogen-Substituted Indoles as Potential DYRK1A Inhibitors. *Molecules*, **2019**, 24,	4.8	11
196	Structural Insights into Interaction Mechanisms of Alternative Piperazine-urea YEATS Domain Binders in MLLT1. *ACS Medicinal Chemistry Letters*, **2019**, 10, 1661-1666	4.3	15

195	An Activity-Based Probe Targeting Non-Catalytic, Highly Conserved Amino Acid Residues within Bromodomains. *Angewandte Chemie*, **2019**, 131, 1019-1024	3.6	3
194	Single-Molecule Protein Phosphorylation and Dephosphorylation by Nanopore Enzymology. *ACS Nano*, **2019**, 13, 633-641	16.7	29
193	Furo[3,2-b]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway. *Angewandte Chemie - International Edition*, **2019**, 58, 1062-1066	16.4	18
192	Oocyte DNA damage quality control requires consecutive interplay of CHK2 and CK1 to activate p63. *Nature Structural and Molecular Biology*, **2018**, 25, 261-269	17.6	66
191	Large-scale analysis of water stability in bromodomain binding pockets with grand canonical Monte Carlo. *Communications Chemistry*, **2018**, 1,	6.3	38
190	Identifying Small-Molecule Binding Sites for Epigenetic Proteins at Domain-Domain Interfaces. *ChemMedChem*, **2018**, 13, 1051-1057	3.7	6
189	Halogen-Aromatic Interactions Modulate Inhibitor Residence Times. *Angewandte Chemie - International Edition*, **2018**, 57, 7220-7224	16.4	31
188	Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. *Nature Communications*, **2018**, 9, 476	17.4	31
187	Halogenaromatische Wechselwirkungen modulieren die Verweilzeit von Inhibitoren. *Angewandte Chemie*, **2018**, 130, 7338-7343	3.6	1
186	Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells. *Cancer Letters*, **2018**, 428, 160-172	9.9	24
185	A Pseudo-Kinase Double Act. *Structure*, **2018**, 26, 527-528	5.2	0
184	Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1. *Biochemistry*, **2018**, 57, 2140-2149	3.2	13
183	Discovery of a novel allosteric inhibitor scaffold for polyadenosine-diphosphate-ribose polymerase 14 (PARP14) macrodomain 2. *Bioorganic and Medicinal Chemistry*, **2018**, 26, 2965-2972	3.4	20
182	Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung. *Angewandte Chemie*, **2018**, 130, 4456-4470	3.6	8
181	The Cysteinome of Protein Kinases as a Target in Drug Development. *Angewandte Chemie - International Edition*, **2018**, 57, 4372-4385	16.4	110
180	Chemoproteomics and Chemical Probes for Target Discovery. *Trends in Biotechnology*, **2018**, 36, 1275-1286	15.1	57
179	Targeting Pim Kinases and DAPK3 to Control Hypertension. *Cell Chemical Biology*, **2018**, 25, 1195-1207.e82	8.2	5
178	BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E8668-E8677	11.5	28

177	An AKAP-Lbc-RhoA interaction inhibitor promotes the translocation of aquaporin-2 to the plasma membrane of renal collecting duct principal cells. *PLoS ONE*, **2018**, 13, e0191423	3.7	22
176	Mammary molecular portraits reveal lineage-specific features and progenitor cell vulnerabilities. *Journal of Cell Biology*, **2018**, 217, 2951-2974	7.3	20
175	Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement. *Cell Chemical Biology*, **2018**, 25, 206-214.e11	8.2	109
174	Innenr□ktitelbild: Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung (Angew. Chem. 16/2018). *Angewandte Chemie*, **2018**, 130, 4517-4517	3.6	
173	Structure-Based Approach toward Identification of Inhibitory Fragments for Eleven-Nineteen-Leukemia Protein (ENL). *Journal of Medicinal Chemistry*, **2018**, 61, 10929-10934	8.3	20
172	Discovery of an MLLT1/3 YEATS Domain Chemical Probe. *Angewandte Chemie - International Edition* , **2018**, 57, 16302-16307	16.4	32
171	Binding Kinetics Survey of the Drugged Kinome. *Journal of the American Chemical Society*, **2018**, 140, 15774-15782	16.4	35
170	Structure of a glutamine donor mimicking inhibitory peptide shaped by the catalytic cleft of microbial transglutaminase. *FEBS Journal*, **2018**, 285, 4684-4694	5.7	7
169	Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine Scaffold. *Journal of Medicinal Chemistry*, **2018**, 61, 5350-5366	8.3	27
168	Donated chemical probes for open science. *ELife*, **2018**, 7,	8.9	48
167	Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype. *PLoS ONE*, **2018**, 13, e0196761	3.7	14
166	The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer. *Oncogene*, **2017**, 36, 122-132	9.2	93
165	Identification of CLK1 Inhibitors by a Fragment-linking Based Virtual Screening. *Molecular Informatics*, **2017**, 36, 1600123	3.8	1
164	Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies. *Journal of Medicinal Chemistry*, **2017**, 60, 668-680	8.3	28
163	A Specific and Covalent JNK-1 Ligand Selected from an Encoded Self-Assembling Chemical Library. *Chemistry - A European Journal*, **2017**, 23, 8152-8155	4.8	41
162	Hyperactive locomotion in a model is a functional readout for the synaptic abnormalities underlying fragile X syndrome. *Science Signaling*, **2017**, 10,	8.8	18
161	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. *Cell Reports*, **2017**, 19, 2045-2059	10.6	72
160	CBP/p300 Bromodomains Regulate Amyloid-like Protein Aggregation upon Aberrant Lysine Acetylation. *Cell Chemical Biology*, **2017**, 24, 9-23	8.2	27

159	Predictions of Ligand Selectivity from Absolute Binding Free Energy Calculations. *Journal of the American Chemical Society*, **2017**, 139, 946-957	16.4	94
158	Discovery of a PCAF Bromodomain Chemical Probe. *Angewandte Chemie - International Edition*, **2017**, 56, 827-831	16.4	58
157	Discovery of a Selective Allosteric Inhibitor Targeting Macrodomain 2 of Polyadenosine-Diphosphate-Ribose Polymerase 14. *ACS Chemical Biology*, **2017**, 12, 2866-2874	4.9	25
156	Progress towards a public chemogenomic set for protein kinases and a call for contributions. *PLoS ONE*, **2017**, 12, e0181585	3.7	81
155	Characterization of a highly selective inhibitor of the Aurora kinases. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 4405-4408	2.9	5
154	Selective Targeting of Bromodomains of the Bromodomain-PHD Fingers Family Impairs Osteoclast Differentiation. *ACS Chemical Biology*, **2017**, 12, 2619-2630	4.9	20
153	Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of Proteins. *Journal of Medicinal Chemistry*, **2017**, 60, 6998-7011	8.3	20
152	NEK1 kinase domain structure and its dynamic protein interactome after exposure to Cisplatin. *Scientific Reports*, **2017**, 7, 5445	4.9	14
151	F NMR isotropic chemical shift for efficient screening of fluorinated fragments which are racemates and/or display multiple conformers. *Magnetic Resonance in Chemistry*, **2017**, 55, 1091-1095	2.1	7
150	DYRK1B mutations associated with metabolic syndrome impair the chaperone-dependent maturation of the kinase domain. *Scientific Reports*, **2017**, 7, 6420	4.9	14
149	Statistical Analysis on the Performance of Molecular Mechanics Poisson-Boltzmann Surface Area versus Absolute Binding Free Energy Calculations: Bromodomains as a Case Study. *Journal of Chemical Information and Modeling*, **2017**, 57, 2203-2221	6.1	69
148	Pharmacoproteomic characterisation of human colon and rectal cancer. *Molecular Systems Biology*, **2017**, 13, 951	12.2	28
147	Structures of PGAM5 Provide Insight into Active Site Plasticity and Multimeric Assembly. *Structure*, **2017**, 25, 1089-1099.e3	5.2	16
146	Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer. *Nature Communications*, **2017**, 8, 15921	17.4	53
145	BRD4 localization to lineage-specific enhancers is associated with a distinct transcription factor repertoire. *Nucleic Acids Research*, **2017**, 45, 127-141	20.1	64
144	The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer. *Clinical Cancer Research*, **2017**, 23, 2027-2037	12.9	41
143	Dietary Compound Resveratrol Is a Pan-BET Bromodomain Inhibitor. *Nutrients*, **2017**, 9,	6.7	9
142	Atad2 is a generalist facilitator of chromatin dynamics in embryonic stem cells. *Journal of Molecular Cell Biology*, **2016**, 8, 349-62	6.3	43

141	Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B. *Journal of Medicinal Chemistry*, **2016**, 59, 1410-24	8.3	108
140	Emerging Target Families: Intractable Targets. *Handbook of Experimental Pharmacology*, **2016**, 232, 43-58	3.2	8
139	Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. *Cancer Cell*, **2016**, 30, 273-289	24.3	92
138	Thermodynamic properties of leukotriene A hydrolase inhibitors. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 5243-5248	3.4	10
137	Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia. *Science Advances*, **2016**, 2, e1600760	14.3	64
136	An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f] quinazoline-2-carbimidates (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases. *Journal of Medicinal Chemistry*, **2016**, 59, 10315-10321	8.3	25
135	Cardiac myosin light chain is phosphorylated by Ca2+/calmodulin-dependent and -independent kinase activities. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E3824-33	11.5	25
134	Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure. *European Journal of Medicinal Chemistry* , **2016**, 118, 170-7	6.8	24
133	Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF. *Journal of Medicinal Chemistry*, **2016**, 59, 1642-7	8.3	68
132	The Intersection of Structural and Chemical Biology - An Essential Synergy. *Cell Chemical Biology*, **2016**, 23, 173-182	8.2	14
131	Epigenomic regulation of oncogenesis by chromatin remodeling. *Oncogene*, **2016**, 35, 4423-36	9.2	64
130	Structure of the Human Protein Kinase ZAK in Complex with Vemurafenib. *ACS Chemical Biology*, **2016**, 11, 1595-602	4.9	11
129	Accurate calculation of the absolute free energy of binding for drug molecules. *Chemical Science*, **2016**, 7, 207-218	9.4	169
128	Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor. *Journal of Medicinal Chemistry* , **2016**, 59, 4462-75	8.3	127
127	Structure-Based Identification of Inhibitory Fragments Targeting the p300/CBP-Associated Factor Bromodomain. *Journal of Medicinal Chemistry*, **2016**, 59, 1648-53	8.3	34
126	Comprehensive characterization of the Published Kinase Inhibitor Set. *Nature Biotechnology*, **2016**, 34, 95-103	44.5	191
125	Effect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability. *PLoS ONE*, **2016**, 11, e0159180	3.7	14
124	Quality control in oocytes by p63 is based on a spring-loaded activation mechanism on the molecular and cellular level. *ELife*, **2016**, 5,	8.9	31

123	Novel p38 MAP kinase inhibitors identified from yoctoReactor DNA-encoded small molecule library. *MedChemComm*, **2016**, 7, 1332-1339	5	54
122	BET inhibition as a new strategy for the treatment of gastric cancer. *Oncotarget*, **2016**, 7, 43997-44012	3.3	35
121	Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket. *Cell Chemical Biology*, **2016**, 23, 1335-1340	8.2	62
120	Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit. *Journal of Medicinal Chemistry*, **2016**, 59, 4800-11	8.3	52
119	Co-crystal structures of the protein kinase haspin with bisubstrate inhibitors. *Acta Crystallographica Section F, Structural Biology Communications*, **2016**, 72, 339-45	1.1	5
118	Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk. *Nature Chemical Biology*, **2016**, 12, 504-10	11.7	32
117	Family-wide Structural Analysis of Human Numb-Associated Protein Kinases. *Structure*, **2016**, 24, 401-11	5.2	84
116	Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex. *Journal of Medicinal Chemistry*, **2016**, 59, 5095-101	8.3	35
115	Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis. *Journal of Medicinal Chemistry*, **2016**, 59, 8787-8803	8.3	32
114	Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors. *Journal of Medicinal Chemistry*, **2016**, 59, 8889-8912	8.3	43
113	Mechanism of TAp73 inhibition by Np63 and structural basis of p63/p73 hetero-tetramerization. *Cell Death and Differentiation*, **2016**, 23, 1930-1940	12.7	22
112	Discovery of New Bromodomain Scaffolds by Biosensor Fragment Screening. *ACS Medicinal Chemistry Letters*, **2016**, 7, 1213-1218	4.3	14
111	Preclinical target validation using patient-derived cells. *Nature Reviews Drug Discovery*, **2015**, 14, 149-50	64.1	40
110	Design and synthesis of potent and selective inhibitors of BRD7 and BRD9 bromodomains. *MedChemComm*, **2015**, 6, 1381-1386	5	52
109	The promise and peril of chemical probes. *Nature Chemical Biology*, **2015**, 11, 536-41	11.7	523
108	Probing the epigenome. *Nature Chemical Biology*, **2015**, 11, 542-5	11.7	29
107	Type II Inhibitors Targeting CDK2. *ACS Chemical Biology*, **2015**, 10, 2116-25	4.9	53
106	LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor. *Angewandte Chemie - International Edition*, **2015**, 54, 6217-21	16.4	113

105	10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A. *Journal of Medicinal Chemistry*, **2015**, 58, 3131-43	8.3	70
104	Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti-Hepatitis C Agents. *Journal of Medicinal Chemistry*, **2015**, 58, 3393-410	8.3	44
103	Structure enabled design of BAZ2-ICR, a chemical probe targeting the bromodomains of BAZ2A and BAZ2B. *Journal of Medicinal Chemistry*, **2015**, 58, 2553-9	8.3	74
102	The ins and outs of selective kinase inhibitor development. *Nature Chemical Biology*, **2015**, 11, 818-21	11.7	174
101	CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 10768-73	11.5	150
100	Differential Recognition Preferences of the Three Src Homology 3 (SH3) Domains from the Adaptor CD2-associated Protein (CD2AP) and Direct Association with Ras and Rab Interactor 3 (RIN3). *Journal of Biological Chemistry*, **2015**, 290, 25275-92	5.4	24
99	Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. *Cancer Research*, **2015**, 75, 5106-5119	10.1	155
98	PIM kinase-responsive microsecond-lifetime photoluminescent probes based on selenium-containing heteroaromatic tricycle. *RSC Advances*, **2015**, 5, 96750-96757	3.7	8
97	Defined PEG smears as an alternative approach to enhance the search for crystallization conditions and crystal-quality improvement in reduced screens. *Acta Crystallographica Section D: Biological Crystallography*, **2015**, 71, 1627-39		35
96	Pim Kinase Inhibitors Evaluated with a Single-Molecule Engineered Nanopore Sensor. *Angewandte Chemie - International Edition*, **2015**, 54, 8154-9	16.4	20
95	Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance. *Science Advances*, **2015**, 1, e1500723	14.3	76
94	Molecular basis of histone tail recognition by human TIP5 PHD finger and bromodomain of the chromatin remodeling complex NoRC. *Structure*, **2015**, 23, 80-92	5.2	44
93	Bisubstrate inhibitor approach for targeting mitotic kinase Haspin. *Bioconjugate Chemistry*, **2015**, 26, 225-34	6.3	10
92	Copper is required for oncogenic BRAF signalling and tumorigenesis. *Nature*, **2014**, 509, 492-6	50.4	288
91	Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. *Nature Chemical Biology*, **2014**, 10, 305-12	11.7	251
90	Targeting bromodomains: epigenetic readers of lysine acetylation. *Nature Reviews Drug Discovery*, **2014**, 13, 337-56	64.1	880
89	Structure of cyclin G-associated kinase (GAK) trapped in different conformations using nanobodies. *Biochemical Journal*, **2014**, 459, 59-69	3.8	36
88	Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?. *ACS Chemical Biology*, **2014**, 9, 1230-41	4.9	266

87	A series of potent CREBBP bromodomain ligands reveals an induced-fit pocket stabilized by a cation-□interaction. *Angewandte Chemie - International Edition*, **2014**, 53, 6126-30	16.4	94
86	[1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains. *Journal of Medicinal Chemistry*, **2014**, 57, 462-76	8.3	75
85	Discovery of BET bromodomain inhibitors and their role in target validation. *MedChemComm*, **2014**, 5, 288-296	5	31
84	Structure-based approaches towards identification of fragments for the low-druggability ATAD2 bromodomain. *MedChemComm*, **2014**, 5, 1843-1848	5	41
83	Machine-assisted synthesis of modulators of the histone reader BRD9 using flow methods of chemistry and frontal affinity chromatography. *MedChemComm*, **2014**, 5, 540-546	5	38
82	Recently targeted kinases and their inhibitors-the path to clinical trials. *Current Opinion in Pharmacology*, **2014**, 17, 58-63	5.1	45
81	Modulation of the chromatin phosphoproteome by the Haspin protein kinase. *Molecular and Cellular Proteomics*, **2014**, 13, 1724-40	7.6	25
80	Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. *Journal of the American Chemical Society*, **2014**, 136, 9308-19	16.4	198
79	Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching. *Epigenetics and Chromatin*, **2014**, 7, 14	5.8	58
78	A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. *Nature Chemical Biology*, **2014**, 10, 853-60	11.7	135
77	Selective Targeting of Protein Interactions Mediated by BET Bromodomains **2014**, 295-308		2
76	Identification of a major determinant for serine-threonine kinase phosphoacceptor specificity. *Molecular Cell*, **2014**, 53, 140-7	17.6	64
75	The structural basis of PI3K cancer mutations: from mechanism to therapy. *Cancer Research*, **2014**, 74, 641-6	10.1	39
74	A comparison of protein kinases inhibitor screening methods using both enzymatic activity and binding affinity determination. *PLoS ONE*, **2014**, 9, e98800	3.7	47
73	Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. *Nature*, **2014**, 508, 222-7	50.4	272
72	Targeting Aberrant Self-Renewal of Leukemic Cells with a Novel CBP/p300 Bromodomain Inhibitor. *Blood*, **2014**, 124, 3750-3750	2.2	1
71	The design and synthesis of 5- and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains. *MedChemComm*, **2013**, 4, 140-144	5	58
70	Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition. *Structure*, **2013**, 21, 986-96	5.2	99

69	Mechanism and consequence of the autoactivation of p38 mitogen-activated protein kinase promoted by TAB1. *Nature Structural and Molecular Biology*, **2013**, 20, 1182-90	17.6	69
68	Stochastic detection of Pim protein kinases reveals electrostatically enhanced association of a peptide substrate. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E4417-26	11.5	41
67	A public-private partnership to unlock the untargeted kinome. *Nature Chemical Biology*, **2013**, 9, 3-6	11.7	119
66	Bromo-deaza-SAH: a potent and selective DOT1L inhibitor. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 1787-1794	3.4	54
65	Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases. *ACS Medicinal Chemistry Letters*, **2013**, 4, 22-26	4.3	57
64	Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening. *Journal of Medicinal Chemistry*, **2013**, 56, 8073-88	8.3	100
63	Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain. *Journal of Medicinal Chemistry*, **2013**, 56, 10183-7	8.3	85
62	PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. *Cancer Research* , **2013**, 73, 3336-46	10.1	191
61	Small-molecule modulators for epigenetics targets. *ChemMedChem*, **2013**, 8, 1885-91	3.7	19
60	Selective bisubstrate inhibitors with sub-nanomolar affinity for protein kinase Pim-1. *ChemMedChem*, **2013**, 8, 909-13	3.7	17
59	Testis specific gene expression drives disease progression and Rituximab resistance in lymphoma. *EMBO Molecular Medicine*, **2013**, 5, 1149-50	12	
58	RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 19754-9	11.5	305
57	Stimulation of Hepatic Apolipoprotein A-I Production by Novel Thieno-Triazolodiazepines: Roles of the Classical Benzodiazepine Receptor, PAF Receptor, and Bromodomain Binding. *Lipid Insights*, **2013**, 6, 47-54	1	13
56	Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 1878-86	3.4	90
55	7,8-dichloro-1-oxo- carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes. *Journal of Medicinal Chemistry*, **2012**, 55, 403-13	8.3	56
54	Small-molecule inhibition of BRDT for male contraception. *Cell*, **2012**, 150, 673-84	56.2	277
53	Crystal structure of human aurora B in complex with INCENP and VX-680. *Journal of Medicinal Chemistry*, **2012**, 55, 7841-8	8.3	55
52	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. *Journal of Medicinal Chemistry*, **2012**, 55, 9831-7	8.3	157

51	Analysis of conditions affecting auto-phosphorylation of human kinases during expression in bacteria. *Protein Expression and Purification*, **2012**, 81, 136-143	2	27
50	Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions. *Journal of Medicinal Chemistry*, **2012**, 55, 9393-413	8.3	140
49	The bromodomain interaction module. *FEBS Letters*, **2012**, 586, 2692-704	3.8	267
48	Histone recognition and large-scale structural analysis of the human bromodomain family. *Cell*, **2012**, 149, 214-31	56.2	1054
47	Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. *Journal of Medicinal Chemistry*, **2012**, 55, 9312-30	8.3	146
46	Kinase inhibitor selectivity profiling using differential scanning fluorimetry. *Methods in Molecular Biology*, **2012**, 795, 109-18	1.4	100
45	Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. *Journal of Medicinal Chemistry*, **2012**, 55, 7346-59	8.3	224
44	A small-molecule inhibitor of Haspin alters the kinetochore functions of Aurora B. *Journal of Cell Biology*, **2012**, 199, 269-84	7.3	74
43	Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva. *Journal of Biological Chemistry*, **2012**, 287, 36990-8	5.4	128
42	Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. *Molecular BioSystems*, **2011**, 7, 2899-908		117
41	Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class. *Journal of Medicinal Chemistry*, **2011**, 54, 2359-67	8.3	28
40	DNA damage in oocytes induces a switch of the quality control factor TAp63 from dimer to tetramer. *Cell*, **2011**, 144, 566-76	56.2	93
39	Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. *Journal of Medicinal Chemistry*, **2011**, 54, 4172-86	8.3	107
38	Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. *Chemistry and Biology*, **2011**, 18, 67-76		154
37	High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. *Chemistry and Biology*, **2011**, 18, 868-79		88
36	3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. *Journal of Medicinal Chemistry*, **2011**, 54, 6761-70	8.3	177
35	Bromodomains as therapeutic targets. *Expert Reviews in Molecular Medicine*, **2011**, 13, e29	6.7	327
34	Selective inhibition of BET bromodomains. *Nature*, **2010**, 468, 1067-73	50.4	2725

33	The (un)targeted cancer kinome. *Nature Chemical Biology*, **2010**, 6, 166-169	11.7	234
32	Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. *Nature Chemical Biology*, **2010**, 6, 359-68	11.7	178
31	Structure and functional characterization of the atypical human kinase haspin. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 20198-203	11.5	115
30	Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. *Structure*, **2009**, 17, 128-38	5.2	156
29	Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation. *Structure*, **2009**, 17, 352-62	5.2	81
28	Large-scale structural analysis of the classical human protein tyrosine phosphatome. *Cell*, **2009**, 136, 352-63	56.2	344
27	Activation segment dimerization: a mechanism for kinase autophosphorylation of non-consensus sites. *EMBO Journal*, **2008**, 27, 704-14	13	128
26	Structure of the human protein kinase MPSK1 reveals an atypical activation loop architecture. *Structure*, **2008**, 16, 115-24	5.2	30
25	Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. *Cell*, **2008**, 134, 793-803	56.2	171
24	Linear motif atlas for phosphorylation-dependent signaling. *Science Signaling*, **2008**, 1, ra2	8.8	342
23	Insights for the development of specific kinase inhibitors by targeted structural genomics. *Drug Discovery Today*, **2007**, 12, 365-72	8.8	57
22	Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs. *Structure*, **2007**, 15, 201-13	5.2	95
21	Activation segment exchange: a common mechanism of kinase autophosphorylation?. *Trends in Biochemical Sciences*, **2007**, 32, 351-6	10.3	78
20	Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. *Cancer Research*, **2007**, 67, 6916-24	10.1	166
19	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 20523-8	11.5	286
18	Inhibition of protein-protein interactions: the discovery of druglike beta-catenin inhibitors by combining virtual and biophysical screening. *Proteins: Structure, Function and Bioinformatics*, **2006**, 64, 60-7	4.2	158
17	Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. *Journal of Medicinal Chemistry*, **2005**, 48, 7604-14	8.3	131
16	Structure and substrate specificity of the Pim-1 kinase. *Journal of Biological Chemistry*, **2005**, 280, 41675-82	34	147

15	NMR-Based screening with competition water-ligand observed via gradient spectroscopy experiments: detection of high-affinity ligands. *Journal of Medicinal Chemistry*, **2002**, 45, 2610-4	8.3	106
14	Thermal unfolding of small proteins with SH3 domain folding pattern. *Proteins: Structure, Function and Bioinformatics*, **1998**, 31, 309-19	4.2	49
13	Thermodynamic characterization of non-sequence-specific DNA-binding by the Sso7d protein from Sulfolobus solfataricus. *Journal of Molecular Biology*, **1998**, 276, 775-86	6.5	79
12	Crystal structure of glutamate dehydrogenase from the hyperthermophilic eubacterium Thermotoga maritima at 3.0 A resolution. *Journal of Molecular Biology*, **1997**, 267, 916-32	6.5	142
11	Thermal unfolding of the DNA-binding protein Sso7d from the hyperthermophile Sulfolobus solfataricus. *Journal of Molecular Biology*, **1996**, 264, 1132-44	6.5	87
10	Crystallization and crystal packing of recombinant 3 (or 17) beta-hydroxysteroid dehydrogenase from Comamonas testosteroni ATTC 11996. *FEBS Journal*, **1996**, 236, 144-8		13
9	Crystallization and preliminary crystallographic analysis of an amylopullulanase from the hyperthermophilic archaeon Pyrococcus woesei. *Proteins: Structure, Function and Bioinformatics*, **1995**, 23, 595-7	4.2	9
8	Preliminary crystallographic analysis of an extremely thermostable glutamate dehydrogenase from the archaeon Pyrococcus woesei. *Acta Crystallographica Section D: Biological Crystallography*, **1995**, 51, 395-8		1
7	Unc-51-Like Kinase 3 (ULK3) In Complex With Bosutinib		2
6	SGC-GAK-1: a chemical probe for cyclin G associated kinase (GAK)		1
5	The Kinase Chemogenomic Set (KCGS): An open science resource for kinase vulnerability identification		4
4	Parkinson Disease-linked LRRK2 structure and model for microtubule interaction		9
3	A structure-based approach towards identification of inhibitory fragments for eleven-nineteen-leukemia protein (ENL) YEATS domain		1
2	Structural insights into interaction mechanisms of alternative piperazine-urea YEATS domain binders in MLLT1		1
1	Mutation in Abl kinase with altered drug binding kinetics indicates a novel mechanism of imatinib resistance		1